Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Batoclimab in Active Thyroid Eye Disease
2022-002788-30Phase 3Active
- Sponsor
- Immunovant, Inc.
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in Graves Orbitopathy (GO) comparing Batoclimab with Placebo (2 arms). Primary endpoint: Proptosis responder rate at Week 24. Started Nov 2022; status: active.
02
Drugs
batoclimab
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2022-002788-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002788-30.